Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

What Is the Significance of Variant Histology in Urothelial Carcinoma?

Lobo N, Shariat SF, Guo CC, Fernandez MA, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA 3rd, Roupret M, Kamat AM.

Eur Urol Focus. 2019 Sep 14. pii: S2405-4569(19)30278-0. doi: 10.1016/j.euf.2019.09.003. [Epub ahead of print] Review.

PMID:
31530497
2.

Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.

Thapi S, Leiter A, Galsky M, Gallagher EJ.

J Immunother Cancer. 2019 Sep 12;7(1):248. doi: 10.1186/s40425-019-0729-3.

3.

Clinical Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Call for Standardized Assessments and Definitions.

Winoker JS, Liaw CW, Galsky MD, Wiklund P, Mehrazin R.

Eur Urol Focus. 2019 Sep 4. pii: S2405-4569(19)30227-5. doi: 10.1016/j.euf.2019.08.009. [Epub ahead of print] Review.

PMID:
31494093
4.

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC; RISC Investigators.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30001-X. doi: 10.1016/j.euo.2018.12.013. [Epub ahead of print]

PMID:
31411990
5.

Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder.

Stensland KD, Zaid H, Broadwin M, Sorcini A, Canes D, Galsky M, Moinzadeh A.

Eur Urol Oncol. 2018 Nov 30. pii: S2588-9311(18)30195-0. doi: 10.1016/j.euo.2018.11.003. [Epub ahead of print]

PMID:
31411987
6.

The clinical and economic burden of perioperative complications of radical cystectomy.

Liaw CW, Winoker JS, Wiklund P, Sfakianos J, Galsky MD, Mehrazin R.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S277-S279. doi: 10.21037/tau.2019.03.04. No abstract available.

7.

Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R.

Eur Urol. 2019 Oct;76(4):524-532. doi: 10.1016/j.eururo.2019.07.032. Epub 2019 Jul 28.

PMID:
31362898
8.

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.

Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP.

J Clin Oncol. 2019 Jul 29:JCO1901140. doi: 10.1200/JCO.19.01140. [Epub ahead of print]

PMID:
31356140
9.

Conditionally Reprogrammed Patient-derived Cells: A Step Forward Towards Personalized Medicine?

Martini A, Sfakianos JP, Galsky MD.

Eur Urol. 2019 Oct;76(4):435-436. doi: 10.1016/j.eururo.2019.07.015. Epub 2019 Jul 18. No abstract available.

PMID:
31327640
10.

The natural history of untreated muscle-invasive bladder cancer.

Martini A, Sfakianos JP, Renström-Koskela L, Mortezavi A, Falagario UG, Egevad L, Hosseini A, Mehrazin R, Galsky MD, Steineck G, Wiklund NP.

BJU Int. 2019 Jul 16. doi: 10.1111/bju.14872. [Epub ahead of print]

PMID:
31310696
11.

Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database.

Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A; RISC Investigators.

Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30095-1. doi: 10.1016/j.euo.2019.06.014. [Epub ahead of print]

PMID:
31307962
12.

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.

Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Théodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A; RISC Investigators.

Eur Urol. 2019 Oct;76(4):425-429. doi: 10.1016/j.eururo.2019.06.032. Epub 2019 Jul 11.

PMID:
31303258
13.

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.

Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD.

Eur Urol. 2019 Jul 1. pii: S0302-2838(19)30515-9. doi: 10.1016/j.eururo.2019.06.025. [Epub ahead of print]

PMID:
31272788
14.

Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade.

Gong Y, Wang L, Yu H, Alpert N, Cohen MD, Prophete C, Horton L, Sisco M, Park SH, Lee HW, Zelikoff J, Chen LC, Hashim D, Suarez-Farinas M, Donovan MJ, Aaronson SA, Galsky M, Zhu J, Taioli E, Oh WK.

Mol Cancer Res. 2019 Aug;17(8):1605-1612. doi: 10.1158/1541-7786.MCR-19-0115. Epub 2019 Jun 20. Erratum in: Mol Cancer Res. 2019 Aug;17(8):1774.

PMID:
31221798
15.

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.

Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G.

Int J Clin Oncol. 2019 Sep;24(9):1089-1098. doi: 10.1007/s10147-019-01450-w. Epub 2019 Jun 19.

PMID:
31218529
16.

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.

Niglio SA, Jia R, Ji J, Ruder S, Patel VG, Martini A, Sfakianos JP, Marqueen KE, Waingankar N, Mehrazin R, Wiklund P, Oh WK, Mazumdar M, Ferket BS, Galsky MD.

Eur Urol. 2019 Jun 11. pii: S0302-2838(19)30444-0. doi: 10.1016/j.eururo.2019.05.037. [Epub ahead of print] Review.

PMID:
31200951
17.

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.

Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Théodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A.

Eur Urol Oncol. 2019 May;2(3):248-256. doi: 10.1016/j.euo.2018.08.009. Epub 2018 Sep 7.

PMID:
31200838
18.

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY, Powles T, Rosenberg JE, Pal SK, Vaishampayan UN, Necchi A, Wiklund NP, Mehrazin R, Mazumdar M, Sfakianos JP, Galsky MD.

Cancer. 2019 Sep 15;125(18):3155-3163. doi: 10.1002/cncr.32169. Epub 2019 May 31.

PMID:
31150110
19.

The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer.

Waingankar N, Jia R, Marqueen KE, Audenet F, Sfakianos JP, Mehrazin R, Ferket BS, Mazumdar M, Galsky MD.

Urol Oncol. 2019 Sep;37(9):572.e21-572.e28. doi: 10.1016/j.urolonc.2019.04.027. Epub 2019 May 18.

PMID:
31109837
20.

Atezolizumab in "Real World" Patients: Do Phase 3b Trials Help Bridge the Gap Between Efficacy and Effectiveness?

Patel VG, Galsky MD.

Eur Urol. 2019 Jul;76(1):82-83. doi: 10.1016/j.eururo.2019.04.004. Epub 2019 Apr 19. No abstract available.

PMID:
31006493
21.

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice.

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R.

Oncologist. 2019 Jun;24(6):e397-e399. doi: 10.1634/theoncologist.2019-0039. Epub 2019 Apr 3.

PMID:
30944183
22.

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD.

Oncologist. 2019 Apr 1. pii: theoncologist.2018-0739. doi: 10.1634/theoncologist.2018-0739. [Epub ahead of print]

PMID:
30936379
23.

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.

Tohmé R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, Vasireddi N, Dhawan NS, Ma'ayan A, Sharma N, Galsky MD, Ohlmeyer M, Sangodkar J, Narla G.

JCI Insight. 2019 Feb 21;4(4). pii: 125693. doi: 10.1172/jci.insight.125693. eCollection 2019 Feb 21.

24.

Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma.

Martini A, Daza J, Poltiyelova E, Gul Z, Heard JR, Ferket BS, Waingankar N, Galsky MD, Sfakianos JP.

BJU Int. 2019 Feb 23. doi: 10.1111/bju.14719. [Epub ahead of print]

PMID:
30801918
25.

Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States.

Marqueen KE, Waingankar N, Sfakianos JP, Mehrazin R, Niglio SA, Audenet F, Jia R, Mazumdar M, Ferket BS, Galsky MD.

JNCI Cancer Spectr. 2018 Nov;2(4):pky075. doi: 10.1093/jncics/pky075. Epub 2019 Jan 28.

26.

Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer.

Ramos JD, Holt SK, Schade GR, Galsky MD, Wright JL, Gore JL, Yu EY.

BJU Int. 2019 Aug;124(2):290-296. doi: 10.1111/bju.14685. Epub 2019 Feb 19.

PMID:
30667142
27.

Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy.

Azad A, Chang P, Devuni D, Bichoupan K, Kesar V, Branch AD, Oh WK, Galsky MD, Ahmad J, Odin JA.

J Clin Gastroenterol Hepatol. 2018;2(3). pii: 18. doi: 10.21767/2575-7733.1000047. Epub 2018 Sep 14.

28.

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.

Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN.

Front Oncol. 2018 Nov 19;8:463. doi: 10.3389/fonc.2018.00463. eCollection 2018.

29.

A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.

Audenet F, Sfakianos JP, Waingankar N, Ruel NH, Galsky MD, Yuh BE, Gin GE.

Urol Oncol. 2019 Feb;37(2):116-122. doi: 10.1016/j.urolonc.2018.11.011. Epub 2018 Dec 1.

PMID:
30509868
30.

Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.

Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD.

Clin Genitourin Cancer. 2019 Feb;17(1):7-14.e3. doi: 10.1016/j.clgc.2018.09.008. Epub 2018 Sep 13.

PMID:
30292628
31.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20. Review.

PMID:
30238401
32.

Current Role of Checkpoint Inhibitors in Urologic Cancers.

Attalla K, Sfakianos JP, Galsky MD.

Cancer Treat Res. 2018;175:241-258. doi: 10.1007/978-3-319-93339-9_11.

PMID:
30168125
33.

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.

Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD.

Nat Commun. 2018 Aug 29;9(1):3503. doi: 10.1038/s41467-018-05992-x.

34.

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.

Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J.

Cell. 2018 Aug 23;174(5):1200-1215.e20. doi: 10.1016/j.cell.2018.07.015. Epub 2018 Aug 9.

35.

Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.

Khunger M, Rakshit S, Hernandez AV, Pasupuleti V, Glass K, Galsky MD, Grivas P.

Oncologist. 2018 Dec;23(12):1494-1499. doi: 10.1634/theoncologist.2018-0003. Epub 2018 Aug 1.

PMID:
30068783
36.

Resistance to prostate-cancer treatment is driven by immune cells.

Galsky MD.

Nature. 2018 Jul;559(7714):338-339. doi: 10.1038/d41586-018-05460-y. No abstract available.

PMID:
30013202
37.

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.

Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A.

J Urol. 2018 Dec;200(6):1207-1214. doi: 10.1016/j.juro.2018.07.035. Epub 2018 Sep 4.

PMID:
30012366
38.

Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR.

Lee E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, Wang L, Oh WK, Galsky MD, Cordon-Cardo C, Zhu J.

Oncogene. 2018 Nov;37(44):5858-5872. doi: 10.1038/s41388-018-0367-0. Epub 2018 Jul 3.

39.

Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.

Audenet F, Waingankar N, Ferket BS, Niglio SA, Marqueen KE, Sfakianos JP, Galsky MD.

J Urol. 2018 Nov;200(5):996-1004. doi: 10.1016/j.juro.2018.06.001. Epub 2018 Jun 4.

PMID:
29879397
40.

Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.

Audenet F, Farkas AM, Anastos H, Galsky MD, Bhardwaj N, Sfakianos JP.

World J Urol. 2018 Nov;36(11):1741-1748. doi: 10.1007/s00345-018-2359-7. Epub 2018 Jun 2.

PMID:
29860605
41.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF.

Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.

42.

Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.

Galsky MD, Pal SK, Lin SW, Ogale S, Zivkovic M, Simpson J, Derleth C, Schiff C, Sonpavde G.

Bladder Cancer. 2018 Apr 26;4(2):227-238. doi: 10.3233/BLC-170149.

43.

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22.

44.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
45.

Hospital Centralization Impacts High-Risk Lung and Bladder Cancer Surgical Patients.

Lieberman-Cribbin W, Galsky M, Casey M, Liu B, Oh W, Flores R, Taioli E.

Cancer Invest. 2017 Nov 26;35(10):652-661. doi: 10.1080/07357907.2017.1406495.

PMID:
29243986
46.

Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.

Galsky MD.

Nat Rev Urol. 2018 Feb;15(2):71-72. doi: 10.1038/nrurol.2017.199. Epub 2017 Nov 28. Review. No abstract available.

PMID:
29182606
47.

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium Group.

Clin Genitourin Cancer. 2018 Apr;16(2):e483-e490. doi: 10.1016/j.clgc.2017.10.012. Epub 2017 Nov 1.

PMID:
29158079
48.

Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer.

Galsky MD, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Hu L, Tsao CK, Sfakianos J, Mehrazin R, Waingankar N, Oh WK, Mazumdar M, Ferket BS.

JCO Clin Cancer Inform. 2017 Nov;1:1-12. doi: 10.1200/CCI.17.00116.

49.

Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer.

Galsky MD, Shahin M, Jia R, Shaffer DR, Gimpel-Tetra K, Tsao CK, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos JP, Acon P, Oh WK.

JCO Clin Cancer Inform. 2017 Nov;1:1-10. doi: 10.1200/CCI.17.00044.

50.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators.

Ann Oncol. 2018 Feb 1;29(2):361-369. doi: 10.1093/annonc/mdx692.

PMID:
29077785

Supplemental Content

Loading ...
Support Center